Synapse - Find an Expert

5608 Results

Kinase inhibitors as anticancer drugs

Book Section

Iyer, G.; Chakravarty, D.; Solit, D. B.
In DeVita, V. T. Jr; Lawrence, T. S.; Rosenberg, S. A. (Eds.) DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 11th ed (2019)

Fulltext@MSK | Save

A phase II trial of the aurora kinase A inhibitor alisertib for patients with castration-resistant and neuroendocrine prostate cancer: Efficacy and biomarkers

Journal Article

Beltran, H.; Oromendia, C.; Danila, D. C.; Montgomery, B.; Hoimes, C.; Szmulewitz, R. Z.; Vaishampayan, U.; Armstrong, A. J.; Stein, M.; Pinski, J.; more...
Clinical Cancer Research (2019)

Fulltext@MSK | Save

Tumor cell heterogeneity and resistance; Report from the 2018 Coffey-Holden Prostate Cancer Academy Meeting

Review

Miyahira, A. K.; Den, R. B.; Carlo, M. I.; de Leeuw, R.; Hope, T. A.; Karzai, F.; McKay, R. R.; Salami, S. S.; Simons, J. W.; Pienta, K. J.; more...
Prostate (2019)

Fulltext@MSK | Save

Update on systemic prostate cancer therapies: Management of metastatic castration-resistant prostate cancer in the era of precision oncology

Review

Nuhn, P.; De Bono, J. S.; Fizazi, K.; Freedland, S. J.; Grilli, M.; Kantoff, P. W.; Sonpavde, G.; Sternberg, C. N.; Yegnasubramanian, S.; Antonarakis, E. S.
European Urology (2019)

Fulltext@MSK | Save

Genomic differences between “primary” and “secondary” muscle-invasive bladder cancer as a basis for disparate outcomes to cisplatin-based neoadjuvant chemotherapy

Editorial

Pietzak, E. J.; Zabor, E. C.; Bagrodia, A.; Armenia, J.; Hu, W.; Zehir, A.; Funt, S.; Audenet, F.; Barron, D.; Maamouri, N.; more...
European Urology (2019)

Fulltext@MSK | Save

Development of a prediction tool for exclusive locoregional recurrence after radical cystectomy in patients with muscle-invasive bladder cancer

Journal Article

Necchi, A.; Pond, G. R.; Moschini, M.; Plimack, E. R.; Niegisch, G.; Yu, E. Y.; Bamias, A.; Agarwal, N.; Vaishampayan, U.; Theodore, C.; more...
Clinical Genitourinary Cancer (2019)

Fulltext@MSK | Save

Updated recommendations on the diagnosis, management, and clinical trial eligibility criteria for patients with renal medullary carcinoma

Guidelines

Msaouel, P.; Hong, A. L.; Mullen, E. A.; Atkins, M. B.; Walker, C. L.; Lee, C. H.; Carden, M. A.; Genovese, G.; Linehan, W. M.; Rao, P.; more...
Clinical Genitourinary Cancer (2019)

Fulltext@MSK | Save

Circulating tumor cells in prostate cancer: From discovery to clinical utility

Review

Pantel, K.; Hille, C.; Scher, H. I.
Clinical Chemistry (2019)

Fulltext@MSK | Save

PTEN expression, not mutation status in TSC1, TSC2, or mTOR, correlates with the outcome on everolimus in patients with renal cell carcinoma treated on the randomized RECORD-3 trial